Related Experiment Video
Updated: Jul 24, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia
Françoise Huguet1,2, Delphine Réa2,3, Emilie Cayssials2,4
1Hematology Department, Institut Universitaire du Cancer, Centre Hospitalier Universitaire, Toulouse, France.
Introduction:
Ponatinib exhibits a high inhibition potency on wild-type and most mutated forms of the BCR:ABL1 kinase, but also a significant cardiovascular toxicity. Improving the efficacy/safety ratio should allow patients to safely draw benefit from the drug.
Areas Covered:
Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovascular risk management, as well as on the most recent data collected in real-life studies and in a randomized phase II trial, we propose a decision-tree of dose selection of the drug.
Expert Opinion:
We distinguish (1) highly resistant patients according to poor previous response to second generation tyrosine kinase inhibitors (complete hematologic response or less) or to mutational status (T315I, E255V, alone or within compound mutations), requiring a starting daily dose of 45 mg, reduced to 15 or 30 mg according to the patient's profile, preferentially upon major molecular achievement (3-log reduction or MR3, BCR:ABL1 ≤ 0.1%IS); (2) less-resistant patients justifying an initial dose of 30 mg, reduced to 15 mg upon MR2 (BCR:ABL1 ≤ 1%IS) or preferentially MR3 in patients with a favorable safety profile; (3) intolerant patients to be treated by 15 mg.
Insights
This study proposes a ponatinib dosing strategy to balance efficacy and safety in chronic myeloid leukemia patients. The decision-tree optimizes dosage based on resistance and molecular response, aiming to improve patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cardiovascular Medicine
Background:
- Ponatinib is potent against BCR-ABL1 kinase mutations but carries cardiovascular risks.
- Optimizing the efficacy/safety ratio is crucial for patient benefit.
- Existing guidelines inform chronic myeloid leukemia (CML) and cardiovascular risk management.
Purpose of the Study:
- To propose a decision-tree for ponatinib dose selection.
- To improve the efficacy/safety profile of ponatinib treatment.
- To guide clinicians in managing CML patients with ponatinib.
Main Methods:
- Review of pharmacological data and international guidelines.
- Analysis of real-world data and a randomized phase II trial.
- Development of a patient-profile-based dosing algorithm.
Main Results:
- Categorization of patients into highly resistant, less-resistant, and intolerant groups.
- Specific starting and reduced daily doses proposed for each category.
- Dose adjustments are linked to treatment response (MR2, MR3) and safety profile.
Conclusions:
- The proposed decision-tree offers a structured approach to ponatinib dosing.
- This strategy aims to maximize therapeutic benefit while minimizing cardiovascular toxicity.
- Personalized dosing based on resistance and response is key for effective CML management.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:15Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:19Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...